Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

NCT07750158 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Zanzalintinib
BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa
DRUG: Placebo

Sponsor

Exelixis

Collaborators

[object Object]